Drugs / Selicrelumab
Trials 15 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT02157831 | Jul 2005 → Feb 2008 | cancer | Abramson Cancer Center at Penn Medicine | Completed | No outcome recorded |
| Phase 111 trials | ||||||
| Phase 1 | NCT03892525 | Jul 2019 → Apr 2021 | B-cell non-Hodgkin lymphoma | The Lymphoma Academic Research Organisation | Terminated | No outcome recorded |
| Phase 1 | NCT02760797 | May 2016 → Apr 2018 | neoplasm | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT02665416 | Jan 2016 → Oct 2019 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT02588443 | Oct 2015 → Nov 2018 | malignant pancreatic neoplasm | Abramson Cancer Center at Penn Medicine | Completed | No outcome recorded |
| Phase 1 | NCT02304393 | Dec 2014 → Nov 2019 | cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01456585 | Apr 2012 → Apr 2013 | pancreatic adenocarcinoma | Abramson Cancer Center at Penn Medicine | Completed | No outcome recorded |
| Phase 1 | NCT01103635 | Feb 2010 → May 2016 | metastatic melanoma | Abramson Cancer Center at Penn Medicine | Completed | No outcome recorded |
| Phase 1 | NCT01008527 | Oct 2009 → Sep 2013 | melanoma | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
| Phase 1 | NCT00711191 | Jun 2008 → Jan 2011 | pancreatic neoplasm | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT00607048 | Nov 2007 → Jul 2009 | neoplasm | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT02225002 | Jan 2004 → Feb 2006 | cancer | Abramson Cancer Center at Penn Medicine | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT03555149 | Sep 2018 → Sep 2022 | colorectal cancer | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase 1/2 | NCT03424005 | Mar 2018 → Sep 2030 expected | breast cancer | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03193190 | Jul 2017 → Feb 2025 | pancreatic adenocarcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 17 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Selicrelumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02304393 ↗ |
| Known as | CP-870,893 | “CP-870,893 intravenous administration \[IV\] on day 3 of 4-week cycles” NCT00711191 ↗ |
| Known as | RG-7876 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109477 ↗ |
| Known as | RO7009789 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02760797 ↗ |
| Action | Activate | “CD40-specific agonist monoclonal antibody” PMID 23483678 ↗ Jan 2013 |
| Modality | Monoclonal antibody | “CP-870,893 is a fully human, CD40-specific agonist monoclonal antibody (mAb)” PMID 23483678 ↗ Jan 2013 |
| Route | Intravenous | “CP-870,893 is administered intravenously on DAY 3 of a 21-day cycle” NCT00607048 ↗ |
| Target | CD40 | “CD40-specific agonist monoclonal antibody” PMID 23483678 ↗ Jan 2013 |